Patent reform markup
A markup of sweeping legislation to update the U.S. patent system for the first time in 50 years remains on the Senate Judiciary Committee's agenda for June 21 after being held over last week to allow further deliberation. A letter from several Republican committee members to Committee Chair Patrick Leahy, D-Vt., and Ranking Member Arlen Specter, R-Penn., says additional discussion among members, staff, the Patent and Trademark Office, the Department of Justice, and stakeholders is needed. The bill has moved rapidly through both houses of Congress, with contentious provisions including mandatory apportionment of damages, post-grant opposition, the granting of broad rule-making authority to PTO, and possible amendment of the Inequitable Conduct Doctrine (1"The Pink Sheet," June 11, 2007, p. 8)...
You may also be interested in...
With identical patent reform legislation moving rapidly through both houses of Congress, the U.S. Patent and Trademark Office is asking that the inequitable conduct doctrine be revised to encourage applicants to provide more and better information to examiners about their inventions
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.